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Premature ovarian failure (POF), or premature ovarian insufficiency (POI), is characterized by 
the absence or early cessation of menstruation before the age of 40. Clinically this can be seen as 
primary amenorrhea, the complete absence of menstruation, or secondary amenorrhea, the 
development of amenorrhea due to cessation of ovarian function.  POI affects approximately 1% 
of women under the age of 40 years and 0.1% of women under the age of 30.  Most cases of POI 
are idiopathic, as only 10% have a known cause.  We utilized SNP array technology to identify 
novel copy number variations (CNV’s) in 89 women with POI.  Illumina’s (San Diego, CA, 
USA) HumanCNV370-Duo DNA Analysis BeadChip and Human660W-Quad v1 DNA Analysis 
BeadChip were used to identify microdeletions and microduplications on autosomal 
chromosomes.  A total of 198 autosomal CNV’s were identified ranging from 0.1 Mb to 3.4 Mb.  
The Database of Genomic Variants (DGV) was used as a control population.  We identified 
seven novel microdeletions in our POI cohort, six of which contained gene-coding regions: 
8q24.13, 10p15-p14, 10q23.31, 10q26.3, 15q25.2, and 18q21.32.  Two of the novel 
microdeletions contained genes known to cause ovarian failure in knockout mice models, SYCE1 
and CPEB1.  Seventeen novel microduplications were also detected, with the majority of CNV’s 
detected being on autosomal chromosomes rather than the X chromosome.  This pilot study 
demonstrates an association between specific CNV’s and POI and highlights the importance for 
studies with larger samples sizes to confirm the findings and further support the hypothesis.  
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Natalie Engel, MS 
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Furthermore, array technology may be a useful addition to conventional karyotyping when 
evaluating women with POI.  Studies on the genetic factors of POI have public health 
significance because they search for genomic imbalances in a disease that affects 1% of the 
American population.  Finding the genetic causes may lead to effective treatment methods and 
earlier recognition of those at risk, particularly before the onset of amenorrhea.  
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1.0  INTRODUCTION 
The average woman in the American population experiences menopause naturally between 46 
and 54 years of age3.  Premature ovarian failure (POF), or premature ovarian insufficiency (POI), 
is characterized by the absence or early cessation of menstruation before the age of 401. Other 
names include "primary ovarian failure" and "hypergonadotropic hypogonadism"4.  Clinically 
this can be seen as primary amenorrhea, the complete absence of menstruation, or secondary 
amenorrhea, the development of amenorrhea due to cessation of ovarian function.  POI affects 
approximately 1% of women under the age of 40 years and 0.1% of women under the age of 302.  
POI differs from menopause in that 5-10% of women who are diagnosed with POI are able to 
conceive after initial onset4.  POI has important health implications beyond infertility concerns.  
Women with POI have increased mortality when compared to those who experience menopause 
at an average age.  They are known to be at an increased risk for osteoporosis, heart disease, and 
autoimmune diseases5.  Hypoestrogenism for prolonged periods of time can lead to the increased 
risk of hypercholesterolemia, osteoporosis, as well as stroke and other forms of cardiovascular 
diseases2.  Most cases of POI are idiopathic, as only 10% have a known cause.  POI is a highly 
heterogeneous condition and research studies have focused on finding the genetic factors that can 
cause POI.  Several genes have been implicated in women with POI. However, the majority of 
cases still have an unknown cause.  The aim of this pilot study was to determine whether copy 
number variations (CNV’s) are associated with POI.  CNV’s have been implicated in a number 
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of common diseases, including Alzheimer’s disease, Crohn’s disease, autism, and 
schizophrenia6.   Detecting pathologic CNV’s in a cohort of women with POI can lead to 
identifying new candidate genes that affect ovarian function and provide pathways for therapy in 
the future. 
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2.0  BACKGROUND AND SIGNIFICANCE 
2.1 OVERVIEW 
2.1.1 Ovarian Function 
During embryogenesis, the female ovaries form approximately 7 X 106 oocytes at 16-20 weeks 
gestation to begin the process of folliculogenesis7.  After the seventh month of gestation, most of 
these primary oocytes die and the rest enter meiosis and are stored in primordial follicles arrested 
in the diplotene stage of prophase I until puberty7.  At birth, a female has only 20% left of this 
original follicular pool and beginning at puberty 10-15 primordial follicles are recruited in the 
pubertal female each cycle but only 400-500 total are ovulated before menopause7-8.  Unknown 
intra-ovarian factors are important for the initiation of folliculogenesis, whereas follicle-
stimulating hormone (FSH) and luteinizing hormone (LH) are known to play a part in the later 
stages of follicle maturity9.  FSH and LH are hormones released by the anterior pituitary gland7.  
The release of FSH and LH from the pituitary gland stimulates the growth, or maturation, of 
follicles in the ovary as well as estrogen release by the follicle7.  Recruited follicles grow in 
volume and diameter with exposure to FSH and LH, and the amount of granulosa and theca cells 
surrounding the oocyte begin to grow7.  Exposure to gonadotropins at the correct time of growth 
determines which follicle is chosen for ovulation7.  The remaining recruited follicles undergo 
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follicular atresia.  The massive oocyte wastage is important to ensure that only the highest 
quality oocyte is ovulated.   
There are two main ways in which POI is thought to be caused: follicle dysfunction and 
follicle depletion10.  Follicle dysfunction occurs when the follicles are present within the ovary 
but some mechanism is forbidding their growth, resulting in follicular arrest4.  Follicle depletion 
means that the number of follicles present is different from what is expected. This may be due to 
an initial low number of primordial follicles, accelerated atresia at the primary level, or 
autoimmune or toxic destruction of the follicles4. 
2.1.2 POI Presentation and Diagnosis 
Most women who experience POI begin menstruating at a normal age and experience puberty 
normally4.  POI can present in multiple ways as primary amenorrhea is thought to make up only 
10% of POI cases4.  Menses can stop abruptly, cease after the birth of a child or after one has 
stopped taking oral contraceptives, or cessation of menses can follow infrequent menstruation, 
abnormally short cycles, or uncommon uterine bleeding.  Symptoms such as night sweats and hot 
flashes can be seen in some patients. However these are not common4.  
POI is diagnosed by the presence of amenorrhea for at least 4-6 months in a woman less 
than 40 years of age with two elevated follicle-stimulating hormone (FSH) levels taken at least 
one month apart4.    Before menopause, FSH levels drop after ovulation by the negative feedback 
of inhibin and estrogen7.  When menopause is reached, this negative feedback is absent and 
therefore FSH is continually released.  FSH levels greater than 40 IU/l are typically considered in 
the postmenopausal range.  Other markers used to diagnose POI include estradiol levels, Inhibin 
B, anti-Mullerian hormone, and LH10. 
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2.1.3 Consequences and Management of POI 
Infertility is the main consequence associated with POI and can be devastating to couples given 
this diagnosis.  Reproductive assistance is available to women diagnosed with POI and family 
planning options can include use of donor eggs and adoption.  Furthermore, approximately 5-
10% of individuals diagnosed with POI will sporadically ovulate and become pregnant following 
their diagnosis.  In such individuals oocyte reserves are diminished but not exhausted. 
Other health consequences that have been associated with POI are frequently overlooked.  
Women with a diagnosis of POI are at an increased risk of developing heart disease, 
osteoporosis, autoimmune diseases such as hypothyroidism and adrenal insufficiency, and 
deteriorating overall well-being4-5.   Few studies have been dedicated to long-term health 
consequences of women with POI.  The majority of studies in the literature focus on the effects 
of early menopause and hormone deficiencies.  However, the mean age of diagnosis of POI is 
markedly younger than the average age of early menopause.  Hormone deficiency therefore may 
affect women with POI for several years more than those experiencing young menopause and 
this difference may cause more severe health consequences5.  Overall, POI has been associated 
with a 50% higher overall mortality rate than women experiencing natural menopause at an 
average age11.   
Estrogens are important for the formation and maintenance of bone health. Therefore a 
deficiency of these hormones due to inactive ovaries can lead to imbalances in bone formation 
and breakdown12.  Women with POI have been shown to have lower bone density compared to 
controls5.  Bone loss occurs naturally following menopause, and patients with earlier onset POI 
may have never reached their peak bone mass that on average occurs in women in their late 
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twenties5.  Maintaining bone health is an important factor in the management of women with 
POI.   
Increased mortality due to cardiovascular disease has been reported in the literature in 
women with POI12.  Estrogen is known to play a large role in the protection of blood vessels and 
inhibition of atherosclerosis formation13.  Cardiovascular disease risk is greatest in post-
menopausal women and the risk is reduced when estrogen replacement therapy is implemented11-
12.  Cardiovascular mortality has been shown to be increased in women with earlier natural 
menopause compared to women experiencing late natural menopause with an 80% increase risk 
of mortality from ischemic heart disease if menopause is experienced before the age of 40 11-12, 
14.   Low estrogen levels have also been associated with risk factors for cardiovascular disease 
including increased triglycerides, reduced HDL, and reduced insulin sensitivity11, 14-15. 
Few studies have been performed to assess the overall well being of women experiencing 
POI.  Menopause has been known to affect cognitive function as well as memory12. Therefore 
women experiencing POI may be at an increased risk.  In one study, one hundred women with 
premature ovarian failure and a normal karyotype were compared to control women with normal 
menstrual cycles to assess their shyness, self-esteem, and social anxiety levels16. Significant 
differences were seen between controls and women with POI, with cases self-reporting higher 
levels of anxiety and shyness and lower levels of self-esteem16.  Other studies have shown 
increases in hostility and psychological distress in women with POI5, 17-18. 
Autoimmune disorders have been shown to be associated with POI, and at least 20% of 
women with POI will present with an autoimmune disease11, 19.  These autoimmune disorders 
include, but are not limited to, hypothyroidism, diabetes, systemic lupus erythematosus, 
rheumatoid arthritis, and Addison’s disease11.  There is a 50% risk of the development of adrenal 
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insufficiency and Addison’s disease in women with adrenal autoimmunity, which can be fatal if 
unrecognized4, 11.   
Several professional organizations recommend that women with POI undergo a routine 
karyotype and Fragile-X testing, screening for adrenal antibodies, as well as an ultrasound of the 
ovaries and uterus in order to elucidate the cause of their POI20-22.  For those with a positive 
adrenal antibody test, annual evaluation should include a corticotropin stimulation test to monitor 
for adrenal autoimmunity4.  Bone health should be addressed by a bone mineral density test and 
women should be educated regarding strategies to maintain bone health including 1200 mg of 
calcium per day and maintenance of adequate vitamin D status4.  Women should be encouraged 
to exercise appropriately including walking, jogging, and resistance exercising4.  Hormone 
replacement therapy can be considered to eliminate the hypoestrogenism that can lead to the 
increased risks for cardiac disease, osteoporosis, autoimmune adrenal insufficiency, and 
hypothyroidism.  The American Society for Reproductive Medicine and the International 
Menopause Society recommend estrogen-replacement therapy for women with primary ovarian 
insufficiency4. 
2.2 CAUSES OF PREMATURE OVARIAN INSUFFICIENCY 
Most cases of POI are idiopathic as 90% of cases have an unknown cause.  It is a highly 
heterogeneous disease with a wide spectrum of known causes.  Known causes of POI, excluding 
iatrogenic causes such as hysterectomy and oophorectomy, include autoimmune disorders, 
metabolic disorders, and infectious disease, cancer treatments such as radiation or surgery, 
smoking, and genetic causes. 
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2.2.1 Non-Genetic Causes 
Ovarian Toxins 
Chemotherapy and radiation therapy are known to cause premature ovarian insufficiency in 
women receiving them for cancer treatment23.  There is wide variability in how women are 
affected with chemotherapy.  Women under the age of 40 receiving cancer treatments have been 
seen to experience amenorrhea during treatment; menstrual function and fertility have been 
known to return years after treatment has ceased in a subset of women24. Cancer drugs are 
known to affect both dividing somatic cells in the follicles and mature oocytes23.  Alkylating 
agents are more damaging to ovarian cells than non-alkylating agents23.  Drugs such as 
cyclophosphamide have been shown to cause DNA single strand breaks and change base pairs 
and can affect both resting oocytes and dividing follicles.  Studies have shown the effects are age 
and dose dependent, for example, Koyama et al studied the effects of cyclophosphamide on 
premenopausal women23.  Women in their 40’s experienced permanent amenorrhea at an average 
dose of 5.2 g compared to 9.3 g for women in their 30s25.  The argument for this discrepancy is 
the differing number of oocytes still present in these women, presumably with women in their 
30s having more oocytes remaining23.  Radiation therapy is more damaging to ovarian function 
that chemotherapy drugs, and it specifically affects mature oocytes23.  Especially in younger 
women, radiation can cause amenorrhea that resolves after 6 to 18 months, presumably after 
recruitment of a new cohort of primary follicles23-24. Such a response also has been documented 
in women receiving radioactive iodine therapy for thyroid cancer, in whom approximately 30% 
had reversible primary hypogonadism23. 
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Autoimmune disorders 
Autoimmune disorders are seen in approximately 20% of women who present with 
POI19.  Autoimmune oophoritis may occur as part of type I and type II syndromes of 
polyglandular autoimmune failure (PGA), which are associated with auto-antibodies to multiple 
endocrine and other organs4.  The mechanism behind autoimmune oophoritis resulting in POI is 
unknown at this time.  Other autoimmune disorders that have been described with POI include 
insulin dependent diabetes, thyroid autoimmunity, and acetylcholine receptor autoimmunity26.  
In most cases, it is not able to be determined if the autoimmune disease is the cause of POI or a 
secondary complication. 
Other causes 
Different viruses have also been implicated in POI including mumps and HIV24.  
Cigarette smoking is the best-known environmental toxin to affect ovarian function. Those who 
smoke reach menopause approximately two years earlier than nonsmokers24. 
2.2.2 Genetic Basis of POI 
There are several reasons why it is thought that POI can be greatly attributed to genetics.  
Multiple animal and human studies have demonstrated that POI can be caused by single gene 
mutations, including syndromic and non-syndromic forms27.  Second, there is a large familial 
pattern seen with POI.  Studies have found that 4-31% of POI cases are present in a familial 
form2.  Different patterns of inheritance can be seen in pedigrees of families with POF including 
autosomal dominant, autosomal recessive, and X-linked patterns.  Because of the supporting 
factors of a genetic basis for POI, research groups have focused on finding the genetic causes.  
POI has devastating effects on fertility as well as the other health problems. Therefore, early 
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detection of individuals at risk for POI could aid in family planning as well as oocyte 
cryopreservation.  Family studies have shown that POI is a highly heterogeneous multifactorial 
disorder with variable expressivity and reduced penetrance27.  Therefore, even though certain 
genes have now been linked to POI, most cases of POI are still considered idiopathic to date. 
2.2.2.1 Chromosome Disorders 
Chromosome conditions such as Turner syndrome, as well as translocations and inversions, are 
implicated in POI.  Turner syndrome is one of the most common chromosomal defects seen in 
humans and is seen at 1/2500 live births28.  It is caused by the lack of an X chromosome (45,X) 
and its symptoms include webbed neck, short stature, lymphedema in the newborn, and streak 
gonads (fibrous tissue that replaces a functioning gonad)28.  Approximately 50% of patients with 
gonadal dysgenesis are found to have Turner syndrome9. Primary amenorrhea and absence of 
pubertal development is seen in most affected women, however, some have been known to 
develop normally.  The cause for the variability is unknown, but studies between karyotypes and 
phenotype differences in women with X chromosome abnormalities have demonstrated the 
importance of certain X-linked genes to ovarian function and fertility and has led to the 
delineation of three X chromosome critical regions: POF1 at Xq27.2-q27.3, POF2 at Xq13.3-
q22, and a third region at Xp1129.  47,XXX karyotype is also known to be implicated in POI.  
Trisomy X is thought to affect one in one thousand female births, however only 10% are thought 
to be diagnosed28.  In most cases, there are no major health concerns associated with the extra X 
chromosome28.  Multiple case reports in the literature report POI in women with trisomy X, most 
of these reports involve autoimmune disorders as well28.  
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2.2.2.2 Mendelian Disorders 
Monogenic POI can be separated into two categories: syndromic and non-syndromic POI.  There 
are several syndromes known to be associated with POI. Table one outlines the syndromes as 
well as the genes implicated. Typically, patients with one of these syndromes do not present first 
with POI. However, these syndromes should not be overlooked when working up an individual 
affected with POI.   
Table 1. Syndromes Associated with POI27 
Syndrome/Symptoms Gene Position 
Galactosemia GALT 9p13 
Ataxia Telangiectasia ATM 11q22.3 
Frasier Syndrome WT1 11p13 
POF + dilated cardiomyopathy LMNA 1q21.2 
Blepharophimosis-Ptosis-Epicanthus syndrome FOXL2 3q23 
Nijmegen breakage syndrome NBS1 8q21 
Autoimmune polyendocrine syndrome AIRE 21q22.3 
Werner Syndrome RECQ2 8p12-p11.2 
Bloom Syndrome RECQ3 15q26.1 
Rothmund-Thomson syndrome RECQ4 8q24.3 
Vanishing white matter + POF(ovarioleukodystrophy) EIF2B2 14q24 
 
Congenital disorder of glycosylation type Ia 
EIF2B4 2p23.3 
EIF2B5 3q27 
PMM2 16p13.3-p13.2 
Chronic progressive external ophthalmoplegia + POF POLG 15q25 
Mullerian anomalies + adrenal failure + POF SF1 11q13 
Mayer-rokitansky-kuster-hauser syndrome WNT4 1p35 
Fanconi Anemia FA genes  
Lipoid congenital adrenal hyperplasia STAR 8p11.2 
 
Several genes have been implicated in non-syndromic POI and can be seen in table two.  
Most of these genes were discovered through animal studies or through studies on women 
affected with POI.  Only 1-2% of women with POI show a mutation or perturbation in one of 
these genes. Therefore large heterogeneity exists for POI27. 
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Table 2. Genes Known to be Involved in Non-Syndromic POI27 
Gene Position 
BMP15 Xp11.2 
GDF9 5q31.1 
FIGLA 2p12 
NOBOX 7q35 
POF1B Xq21 
DIAPH2 Xq22 
FOXO3 6q21 
FSHR 2p21-p16 
LHR 2p21 
CYP17 10q24.3 
CYP19A1 15q21.1 
FMR1 Xq27.3 
FMR2 Xq28 
 
BMP15 and GDF9 
Bone morphogenic protein 15 (MIM 300247) is part of the TGFβ family and has been 
found to encode an oocyte derived growth and differentiation factor known to be involved in 
follicular development10.  Some of its main roles include the promotion of follicle maturation, 
prevention of cell apoptosis, promotion of oocyte growth, and the regulation of oocyte 
recruitment numbers10.  Most of the research on BMP15 have been done through animal studies 
and have shown BMP15 knockout female mice are subfertile and homozygous mutations in yews 
lead to infertility30.  The BMP15 gene is located on the X chromosome in the third POF critical 
region and studies have shown heterozygous mutations (mostly missense) in the gene in women 
with both primary and secondary amenorrhea30. However, the actual mechanism by which these 
mutations impede BMP15 functionality is presently unknown. 
GDF9 (MIM 601918) is another gene in the TGFβ family known to be associated with 
folliculogenesis and POI.  GDF9 is located at 5q31.1 and like BMP15, animal and functional 
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studies have shown its importance in folliculogenesis27.  Several case control studies have shown 
a possible prevalence of GDF9 heterozygous mutations in POI women of 1.4%; these variants 
have not been found in control samples10. 
BMP15 protein forms homodimers as well as heterodimers with GDF9.  The dominant 
negative hypothesis is a possible mechanism for interrupted ovarian function through 
heterozygous mutations in these genes by contributing to abnormal dimerization of these 
proteins27. 
FIGLA and NOBOX 
FIGLA (MIM 608697) and NOBOX (MIM 610934) are transcription factors and were 
first identified as candidate genes for POI through animal studies31. Mouse models have 
demonstrated the importance of NOBOX in oogenesis and ovarian development based on effects 
of deleting part of the coding region32. This led to accelerated oocyte loss and absent transition of 
primordial germ cells to growing follicles32.  Sequencing of the NOBOX gene in 96 women with 
POI revealed four novel variations, 2 resulting in missense mutations that affected transcription 
binding thus leading to ovarian failure33. Zhao et al 2008 studied one hundred Chinese women 
with POF and identified three variants in four women in the FIGLA gene34.    
POF1B 
POF1B (MIM 300603) maps to the POF2 critical region at Xq21.  POF1B was first 
identified through studying a woman with POI due to an X:autosome balanced translocation35.  
Studies on the effects of POF1B on ovarian function have been mixed.  Several studies have 
found point mutations in POF1B in women with premature ovarian failure, and mouse studies 
have suggested that POF1B is critical for early ovarian development and establishing the final 
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number of germ cells35-36.  Other studies have failed to find mutations or chromosome changes in 
women with POI that disrupt the POF1B gene35. 
DIAPH2 
DIAPH2 (MIM 300108) is the homologue of Drosophila diaphanous (dia), which is 
known to be involved in establishing cell polarity, govern cytokinesis, and reorganize the actin 
cytoskeleton27.  In flies, disturbance of this gene causes sterility.  In one case report, a 
X:autosome translocation affecting the DIAPH2 gene was described in a woman with POI37. 
FOXO3 
Studies on the FOXO3 (MIM 602681) locus have shown it plays a major role in primary 
follicle apoptosis in the mouse38.  Loss of Foxo3 function in the mouse leads to premature 
ovarian failure due to global follicular activation and oocyte death, resulting in sterilization by 15 
weeks of age38.  Studies have identified variations in the FOXO3 gene in women with POI39, 
however it is unknown at this time whether these variations are causal or benign polymorphisms. 
FSHR and LHR 
FSHR (MIM 136435) and LHR (MIM 152790) are hormone receptor proteins and are 
essential for normal reproductive function in both men and women.  Both FSH and LH are 
important sex hormones needed for activation of follicular development and maturation of 
oocytes as well as other processes.  Defects in the FSHR gene can lead to decreased follicle 
growth due to inability to bind FSH or to activate signaling pathways28.  The homozygous 
mutation C566T has been found in many Finnish families studied by Aittomaki et al, 
heterozygous females showed normal fertility40.  This mutation has not been found in other 
ethnic populations, perhaps due to the founder effect among the Finnish.  Abnormal LH levels 
have the potential to lead to disorders such as polycystic ovary syndrome, infertility, and 
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miscarriages28.  A common variant in the LHR gene, G1502A, causes an amino acid substitution 
that may affect LH function, however this hypothesis remains to be proven28.  
CYP17 
CYP17 (MIM 609300) encodes steroid 17-alpha-hydroxylase, and 46,XX patients with a 
defect in this gene may present with primary amenorrhea.  Some studies report cystic follicles in 
these women as well as streak gonads.  The gene is important for male sex patterning, therefore 
the more common finding is sex reversal in 46,XY individuals with defects in this gene27. 
CYP19A1 
CYP19A1 (MIM 107910), located at 15q21.1, codes for aromatase and is involved in the 
conversion of androgens to estrogens.  Two studies have found compound heterozygous 
mutations in the aromatase gene in 2 women presenting with primary amenorrhea and cystic 
ovaries41-42.  In one study, it was shown that the mutant protein exhibited no activity41. 
FMR1 
POI is associated with premutations in the FMR1 gene.  Alleles in the FMR1 gene are 
separated into number of CGG repeats present including normal (6 to 55 repeats), premutation 
(55 to 200 repeats) and full mutation (>200)28.  Approximately 2% of women who present with 
sporadic POI and 14% with familial POI will have a FMR1 premutation4.  Women with 
premutations in the FMR1 gene have a 20% risk of developing FXPOI (Fragile X associated 
POI).  These women are also at risk of having a child with Fragile X syndrome.  Penetrance of 
FXPOI seems to be highest in carriers of mid premutation alleles (80-99 repeats) (18.6%) when 
compared with low repeat numbers (59-79) or high repeat (>100) premutation carriers, 5.9% and 
12.5%, respectively43.  Interestingly, smoking has been found to cause menopause to occur an 
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average of one year earlier in permutation carrier women compared to non-smokers44.  This is 
similar to what is experienced in women who do not carry a premutation in the FMR1 gene. 
FMR2 
FMR 2(MIM 300806) is located distally to FMR1, the gene responsible for Fragile X 
Syndrome.  FMR2 also has a similar pattern of trinucleotide repeat (GCC): normal (<50), 
premutation (50-200) and full mutation variants (>200) as in the FRAXA site of the FMR1 gene.  
Murray et al first reported small alleles (less than 11 repeats) in a cohort of women with POI, but 
no premutations or full mutations45.  In 1999, Murray et al also reported microdeletions in this 
gene in 3 women with POI46. 
2.3 GENOMIC STUDIES AND POI 
2.3.1 Genome Wide Association Studies 
Separate approaches have been used to find genes associated with POI, including targeted gene 
approaches driven by animal models, genome wide association studies (GWAS), linkage 
analysis in families with more than one affected individual, and translocation breakpoint 
mapping47.  Traditionally, use of conventional karyotyping could detect larger deletions, 
duplications, and rearrangements within the genome of women with POI.  With the development 
of microarray technology, array-comparative genomic hybridization (aCGH) platforms can be 
used to detect smaller deletions and duplications that conventional karyotype cannot48. This 
technique involves labeling a reference genome and a test genome with different fluorescent 
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markers, hybridizing to the microarray, and analyzing the intensity of the hybridization signal for 
each clone.   
GWAS can scan the genome of hundreds of POI patients to search for regions that may 
be associated with POI when compared to control samples.  Early GWAS studies on women with 
POI have been sparse but have shown promise.  A study performed on 99 women with idiopathic 
POI and 235 female controls using a SNP array revealed a significant association of one SNP 
contained in the ADAMSTS19 gene49.  This gene is expressed in female mice gonads during 
sexual differentiation49.  No other SNP’s were significantly associated with POI, including those 
in 74 candidate genes selected based on previous literature reports49.   
Kang et al revealed 10 SNPs in the BCKDHB gene that significantly associated with 
POI50.  The authors hypothesized that alterations in this gene may decrease LH levels and 
increase FSH levels through a complex involvement of neurotransmitters and gonadotropin 
stimulation release50.  In this study, 16 patients with POI were matched with 16 controls50.  Kang 
et al later reported the PTHB1 gene to associate with POI and also identified a haplotype in this 
gene that was associated with susceptibility to POI51.  The functional role of PTHB1 is not yet 
known; it is known to be expressed in several tissues including the heart, placenta, liver, kidney, 
and brain51.  Twenty-four individuals with POI and 24 matched controls were used for this 
analysis on a SNP array.  A two step association study was performed, with the first stage based 
off of linkage disequilibrium to identify genes that associate with POI and the second stage 
focused on analyzing additional SNP’s in the PTHB1 gene in a larger population51.  Causative 
SNPs were not identified in the analysis51.   
Another study involving 24 individuals with POI and 24 matched controls revealed 
SNP’s that significantly associated with POI in the PCMT1 gene52. This gene is highly expressed 
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in the human brain and has been associated with epilepsy, spina bifida, and Alzheimer’s 
disease52.  Some reports have found this gene to be expressed in the pituitary gland of rats and is 
a substrate for some pituitary hormones52.  The authors report that PCMT1 is expressed in the 
human pituitary gland and that variants of the gene may lead to an altered structure of the FSH 
receptor binding region52. 
Lacombe et al utilized microarray and linkage analysis to find a region on the X 
chromosome that was homozygous in all daughter affected with POI in a large Lebanese 
family36.  A single point mutation in the POF1B gene, resulting in an amino acid change from 
arginine to glutamine, was reported to be the cause of the POI in the five sisters with POI36.  
Statistical significance were reached in all of these studies for at least one SNP or genomic 
region, however in all of these GWA studies were low numbers of patients and lack of 
reproducing the same results in different populations or ethnic groups of patients. 
2.3.2 Copy Number Variation and SNP Arrays 
Recent studies have shifted their focus to copy number variations (CNV's) in women with POI.  
CNV’s are changes in copy number in a region of the genome.  This can be a gene, a small 
segment of DNA, or an entire chromosome.  CNV’s cover at least 1000 bases and can be benign 
or deleterious as well as inherited or de novo.   CNV’s have been implicated in a number of 
common diseases, including Alzheimer’s disease, Crohn’s disease, autism, and schizophrenia6.   
The use of single nucleotide polymorphism (SNP) arrays for the detection of CNV’s is 
one of the more recent developments in the search for causes of complex diseases.  
Approximately 99% of our base pairs are the same on both chromosomes. The remaining 1% 
represents the diversity that is among the human race, including differences in disease 
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susceptibility53.   SNP’s represent a large portion of this genetic variation between individuals, 
and are defined by a genomic site where there are two nucleotide possibilities, or alleles, each 
possibility appearing in a significant proportion in the population54.  SNP’s are the most common 
genetic variation in the human genome, with over 15 million identified54.  They are highly 
conserved within a population and throughout evolution, and are therefore an excellent marker 
for research6.  SNPs lying in coding regions of the genome are termed either synonymous or 
non-synonymous, depending whether if they change the amino acid sequence 54.  SNP’s lying in 
non-coding regions also have the potential to impact phenotype through changing splicing 
processes or transcription factor binding54.   
SNP arrays were originally designed for fast genotyping of thousands of SNP’s across the 
genome in an individual or population.  Recent use of these arrays to detect copy number 
variation detection has broadened its scope of use in research laboratories.  Analysis of signal 
intensities across the genome can be used to identify regions with multiple SNPs that are deleted 
or duplicated55. These arrays utilize SNP’s spaced across the genome to detect copy number 
variations using statistical software.   
There are several advantages to using SNP arrays to detect CNV’s over other 
applications.  SNP arrays use less sample per experiment compared to array comparative 
genomic hybridization(CGH)56.  Its cost effectiveness allows researchers to test more samples 
per run.  Coverage of SNP arrays allows for this increase in number of samples without 
sacrificing sensitivity56.  SNP arrays allow for parent of origin studies to be conducted as well as 
linkage studies by homozygosity mapping for recessive disorders.  Mosaicism and consanguinity 
can be assessed by SNP arrays, as well as mitotic recombination and gene conversion events, 
unlike array CGH platforms57.  SNP arrays from Illumina and Affymetrix now include hundreds 
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of thousands of SNPs, as well as non-polymorphic probes in regions of the genome where known 
CNV’s are not known to be located58. 
Karyotyping is used to rule out specific causes of POI such as Turner syndrome, trisomy 
X, large deletions and rearrangements, and translocations between autosomal chromosomes and 
the X chromosome.  However, karyotyping suffers from low resolution as it can only detect 
deletions and duplications that are larger than 5 Mb. Microdeletions and microduplications 
therefore cannot be detected by classical cytogenetics, and may be implicated in 15% of all 
human diseases59.  Therefore, use of classical cytogenetics for women with POI may fail to 
identify a large proportion of the genetic causes of the disease.  The use of methods such as 
oligonucleotide arrays and SNP arrays have allowed for a higher resolution and detection of 
microduplications and microdeletions. 
2.3.2.1 SNP Array Methodology 
Illumina is one of the forerunners of SNP array platforms.  Their BeadArray has increased in the 
amount of SNP’s interrogated for each sample from 100,000 to 650,0006.  Illumina platforms 
call for single stranded DNA fragments to hybridize to thousands of probes along the array, each 
designed to bind a specific DNA sequence6.  The signal intensity between the probe and the 
target DNA sequence is used to determine the SNP genotype. 
Every SNP site is determined by sets of probes that are 50 nucleotides in length6.  The 
probe is meant to be complementary to the DNA sequence adjacent to the SNP site.  Each set 
contains probes associated with either the A allele or the B allele of that specific SNP.  The 
probe that is complementary to that SNP site will bind and results in the appropriately colored 
signal(red for A/T, green for C/G)6. Illumina’s computer algorithms are responsible for 
transforming signal colors into genotype calls AA, AB, or BB.  Besides SNP’s, these platforms 
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also interrogate non-SNP CNV regions using additional markers.  These markers are found in 
regions where common CNV’s are known to exist. 
2.3.2.2 SNP Array Data Analysis for CNV Detection 
Illumina’s Genome Studio Genotyping Module Software was developed for use with the 
Illumina platforms.  It can utilize several algorithms, including cnvPartition, designed for 
detecting CNV’s with the GenomeStudio software58.  cnvPartition is capable of generating a 
report of CNV’s in the genome of the samples using confidence values where the user can 
remove CNV’s with low values from further analysis60.  To identify CNV’s across the genome, 
the software utilizes two different measurements to determine the copy number at each SNP.   
B Allele Frequency 
The B allele frequency (BAF) is defined as the ratio of A to B.  For example, at a given 
SNP the possibilities are A(A) or C(B).  The possible genotypes for that SNP are then AA, AB, 
or BB.  After standardization at 0.5, if the genotype is AA, the BAF is given at 0, if the genotype 
is AB the BAF is 0.5, and if the genotype is BB the BAF is 1.  In the case where there is a 
deletion on one chromosome containing the SNP, the BAF could then either be A or B, thus 
making the BAF either 1 or 0.  Duplication on one chromosome containing the SNP can result in 
genotypes of AAB, AAA, ABB, or BBB again altering the BAF. 
Log R Ratio 
The Log R Ratio is defined as the overall fluorescence intensity of the given SNP.  This 
can be standardized at normal copy number = 0. Therefore any fluctuation from this line may be 
due to a CNV.  Table three provides information on expected Log R ratio and BAF readings for 
different CNV’s. 
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Table 3. Copy number state information from SNP array data6 
CNV type Possible SNP genotypes Expected A+B signal Expected BAF 
Homozygous gain 
AAAA 4 0 
AAAB 4 0.25 
AABB 4 0.5 
ABBB 4 0.75 
BBBB 4 1 
Hemizygous gain 
AAA 3 0 
AAB 3 0.33 
ABB 3 0.67 
BBB 3 1 
Normal 
AA 2 0 
AB 2 0.5 
BB 2 1 
Hemizygous loss A- 1 0 B- 1 1 
Homozygous loss - - 0 Undefined 
 
The GenomeStudio software is capable of transforming the raw data from the image scan 
system and converting the signal intensities and colors into the BAF and LRR61.  When the LRR 
and BAF are looked at in unison across a chromosome, a CNV can be distinguished from copy 
neutral loss of heterozygosity (LOH), as well as determining how many copies have been lost or 
duplicated within a region.  cnvPartition compares LRR and BAF values of the alleles in the 
samples to expected values (see table three) to determine CNV regions60.  The user can then 
determine the CNV’s to focus on for their analysis. 
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3.0  METHODS AND MATERIALS 
3.1 SPECIFIC AIM OF STUDY 
The aim of this pilot study was to determine whether CNV's are associated with premature 
ovarian insufficiency. 
Hypothesis: A subset of women with premature ovarian insufficiency harbor pathologic 
microdeletions or microduplications that are not detectable with classical cytogenetics currently 
used for evaluation of POI. 
To test this hypothesis, we utilized SNP array technology on a subset of women with POI 
to delineate whether copy number variants are present on autosomal chromosomes.  Further 
investigation of the genes present in these CNV’s may provide insight into other possible causes 
for idiopathic POI.  Furthermore, the use of genome wide studies may show the need for further 
assessment of women with POI beyond standard karyotyping and FMR1 status screening during 
their initial workup following their diagnosis. 
3.2 RECRUITMENT OF SUBJECTS 
89 women with POI were recruited through Baylor College of Medicine’s POI research study.  
Women were recruited in the Houston, Texas area as well as through the POFsupport.org 
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website, a support group designed for women with POI.  Approval was received from BCM’s 
Institutional Review Board (IRB) as well as the University of Pittsburgh’s IRB.  Inclusion 
criteria for the study included: primary amenorrhea or secondary amenorrhea experienced for at 
least 6 months prior to age 40, and at least one FSH serum level greater than 40 IU/L.  Women 
with a history of pelvic surgery, cancer, radiation exposure, smoking, and genetic syndromes 
associated with POI were excluded from the study.  Of these 89 women, 8 presented with 
primary amenorrhea, 60 presented with secondary amenorrhea, and in 21 cases the type of 
amenorrhea is unknown.  Ages of the subjects at the time of diagnosis ranged from 12 to 39 with 
the average age being 27.  A case was considered familial if the individual had at least one 
family member with a known diagnosis of POI. Table four summarizes the patient population 
and breaks the cohort up into familial versus isolated cases, as well as age of onset of POI. 
Table 4. Subjects by Type of POI and Age at Diagnosis 
 Total Percent of Total 
Number of 
Familial Cases 
Number of 
Idiopathic Cases 
Family history 
unknown 
PA* 8 9% 3 3 2 
<25 17 19% 2 14 1 
25-35 34 38% 6 28 0 
>35 9 10% 0 9 0 
Unknown 21 24% 0 1 20 
 89 100% 11 55 23 
*PA = primary amenorrhea 
3.3 SAMPLE COLLECTION AND PROCESSING 
Peripheral blood samples were collected from all 89 women after informed consent was 
received.  Genomic DNA (gDNA) was extracted from 5 mL of whole blood (Qiagen Puregene 
protocol, Valencia, CA, USA).  gDNA was precipitated by centrifugation and washed with 70% 
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ethanol, then rehydrated overnight in DNA Hydration Solution (Qiagen, Cat # D-5004). DNA 
concentrations were determined on the NanoDrop instrument. 
 Illumina’s (San Diego, CA, USA) HumanCNV370-Duo DNA Analysis BeadChip with 
more than 318,000 tag SNP markers and 52,000 markers targeting additional CNV regions was 
used to examine CNV’s among gDNA for 38 individuals on the BeadArray 500GX.  Illumina’s 
Human660W-Quad v1 DNA Analysis BeadChip with 550,000 tag SNPs and an additional 
100,000 markers targeting common CNV was used for an additional 51 individuals on the iScan 
System.  The median spacing between markers for the arrays was 5.5 kb and 2.5 kb, respectively.  
The array data was analyzed using Illumina’s GenomeStudio Genotyping Module software.   A 
call rate of >99% was accepted as the validity cutoff for each sample on both chips, which 
indicates >99% of the probes successfully identified a genotype.  CNV’s were identified using 
the B-allele frequency and Log R Ratio in GenomeStudio, congruently.  CNV’s were determined 
by visual scanning of all of the chromosomes of the 89 subjects. 
3.3.1 Determination of Novel CNV’s 
All CNV’s were screened against polymorphisms noted in the Database of Genomic Variants 
(DGV; http://projects.tcag.ca/variation).  The DGV is a compilation of common CNV’s detected 
in more than 10,000 healthy individuals, and it has been used as a control population in several 
studies62-64.  The DGV currently reports over 100,000 CNV’s that are found in the control 
samples.  In order for a CNV to be considered present in the control population of the DGV and 
therefore called non-pathogenic, it was present in its entirety in the DGV in the control 
population.  Pearson’s chi squared test was used if needed to determine statistical significance.  
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Microdeletions or microduplications were considered novel and likely pathogenic if not present 
in the DGV. 
3.3.2 Corroboration of Novel Microdeletions 
Quantitative real-time PCR (qPCR) was utilized to corroborate SNP array findings 65.  Emphasis 
was placed on unique microdeletions as opposed to microduplications.  Where possible, a 
relevant protein-coding gene within each deleted region was chosen as a target, and 
oligonucleotides were designed for qPCR analysis (Table 5).  Primers were custom-designed 
through Primer3Plus (http://frodo.wi.mit.edu/primer3).  Table five below lists the primers used 
for qPCR corroboration of the autosomal microdeletions deemed novel in the analysis. 
Table 5. Oligonucleotides designed for qPCR Corroboration of Novel Autosomal Microdeletions 
Within Coding Regions66 
Microdeletion locus Patient Targeted Gene Forward primer (5’ -> 3’) Reverse primer (5’ -> 3’) 
8q24.13 POF-65 FER1L6 CGA ACC ACA GTG CAG 
AAG AA 
AGG GCT ACG TCA TTA 
ATG CT 
10p15-p14 POF-105 AKR1C1 TGT GGA TGG TGA CAC AGA 
GG 
TCT TTC CTT TCT GGC 
CAA TG 
10q23.31 POF-58 STAMBPL1 TAA GCC CAG AAG AGC 
GAG TC 
CGC CAT CCT CTC CAT 
CTC TA 
10q26.3 POF-108 SYCE1 CCA GTG ACA TGG TGG AGT 
TG 
GGT GTC TTC ATT GCC 
ACT CA 
15q25.2 POF-87 CPEB1 CCT GGG TAT TAG CCG ACA 
GT 
AAT CCC GGC ATA CAC 
CAC T 
18q21.32 POF-119 PMAIP1 CAC CGT GTG TAG TTG GCA 
TC 
CCT TCT TCC CAG GCA 
TCT 
 
Quantitative real-time PCR was conducted using 100 ng of gDNA, 0.4 μM forward and 
reverse primers, 1X iQTM SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) and nuclease 
free water, with a total volume of 20 μL per well.  Five replicates were run for each POI 
individual for the targeted gene within each respective deleted region.  A pooled human gDNA 
sample from five unaffected women was used as a control (Promega, Cat # G1521).  Threshold 
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cycle (Ct) values were calculated and averaged for each set of five replicates; these values were 
then used to calculate the standard error of the mean.  The 2-Δ Δ Ct method of quantification was 
used to analyze fold changes in copy number between control (2n) and deleted regions (1n or 
absent).   
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4.0  RESULTS 
Of the 89 women whose gDNA was run on the SNP arrays, 88 were used in the analysis. One 
individual did not pass quality control on the array (call rate of >99%), therefore the subject was 
excluded.  A total of 50 microduplications and 148 microdeletions on autosomal chromosomes, 
ranging in size from 0.1 Mb to 3.4 Mb, were detected.  These CNV’s were found on 72 of the 88 
women.  In order to distinguish novel CNV’s from seemingly benign, non-pathogenic 
imbalances, we compared our data to the Database of Genomic Variants.  33/50 
microduplications and 141/148 microdeletions were present in the control population of the 
DGV.  Therefore, 24 autosomal CNV’s in a total of nineteen women were considered novel.  
There were seven novel autosomal microdeletions (Table 6), one in each of seven different 
women, and seventeen novel autosomal microduplications (Table 7), one in each of eleven 
women and two in each of three women.   
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Table 6. Novel Hemizygous Microdeletions in Cohort of Women with POI66 
 
a Unable to corroborate via qPCR 
bAge at onset of POI unknown; age at time of POI diagnosis indicated 
c Pearson’s chi squared test was used to show statistical significance:  
   3/2,802 control individuals showed a variation of this deletion in the DGV at the indicated locus67-68 
compared to 1.1% in our cohort; P < 0.0001 
d A total of 65 genes deleted; the first and last genes in the deleted interval are listed, as well as the 
BMP15 gene 
Microdeletion Locus Length(Mb) Genes Within Deleted Region Patient Age at  
POI onset 
Family history 
of POI? 
chr 8: 124,964,990-
125,101,913 
0.14 FER1L6 POF-65 36 No 
chr 10: 4,867,522-
5,196,096 
0.33 AKR1E2, AKR1C1,  
AKR1C2, AKR1C3,  
AKR1CL1 
POF-105 35 No 
chr 10: 90,517,549-
90,648,588a 
0.13 LIPN, LIPM,  
ANKRD22, STAMBPL1 
POF-58 36b No 
chr 10: 135,092,227-
135,256,027 c 
0.16 CYP2E1, SYCE1 POF-108 21 Unknown 
chr 14: 40,060,168-
40,305,161 
0.24 None POF-66 31 No 
chr 15: 80,972,574-
82,640,853 
1.67 CPEB1, AP3B2, FSD2,  
HOMER2, WHAMM,  
FAM103A1, C15orf40,  
BTBD1, TM6SF1,  
HDGFRP3, BNC1,  
SH3GL3, ADAMTSL3 
POF-87 PA Sister, aunt 
chr 18: 55,460,039-
55,783,281 
0.32 CCBE1, PMAIP1 POF-119 PA Unknown 
chr X: 48,104,013-
52,083,957 
3.98 SSX4.....BMP15....AK09637 d POF-37 34 No 
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Table 7. Novel Microduplications in Cohort of Women with POI66 
Microduplication locus Length(Mb) Genes within duplicated 
region 
Patient Age at  
POI onset 
Family history  
of POI? 
chr 1: 119,652,659-
119,966,935 
0.31 HAO2, HSD3B2, HSD3B1 POF-106 Unknown Unknown 
chr 1: 119,719,096-
119,953,605 
0.23 HAO2, HSD3B2, HSD3B1 POF-21 33 No 
chr 1: 237,422,778-
237,602,136 
0.18 None POF-56 33 No 
chr 2: 51,536,418-
51,865,782 
0.33 None POF-87 PA Sister, aunt 
chr 3: 7,979,828-
8,127,315 
0.15 None POF-87 PA Sister, aunt 
chr 4: 4,705,258-
4,939,891 
0.23 MSX1 POF-124 Unknown Unknown 
chr 4: 6,003,730-
6,247,313 
0.24 CRMP1, C4orf50, 
JAKMIP1 
POF-124 Unknown Unknown 
chr 6: 57,377,166-
57,503,129 
0.13 PRIM2 POF-34 25 Unknown 
chr 7: 70,257,034-
70,592,167 
0.34 WBSCR17, CALN1 POF-37 34 Unknown 
chr 7: 75,984,206-
79,394,983 
3.41 PMS2L11, CCDC146, FL2, 
PION, PTPN12, 
RSBN1L,TMEM60, PHTF2, 
MAGI2, RPL13AP17 
POF-83 29 No 
chr 7: 97,252,046-
97,393,215 
0.14 ASNS POF-10 PA No 
chr 8: 509,919-835,807 0.33 ERICH1 POF-16 17 No 
chr 8: 2,442,385-
3,126,569 
0.68 CSMD1 POF-45 20 No 
chr 8: 47,626,500-
48,043,110 
0.42 BEYLA POF-13 38 No 
chr 9: 71,619,570-
72,483,319 
0.86 C9orf135, MAMDC2, 
SMC5, KLF9, TRPM3 
POF-119 PA Unknown 
chr 11: 48,556,067-
51,447,829 
2.89 FOLH1, OR4C13, 
OR4C12, OR4A5, OR4C46 
POF-10 PA No 
chr 16: 14,983,979-
16,367,263 
1.38 PCXDC1, NTAN1, RRN3, 
MPV17L, C16orf45, NDE1, 
MIR484, MYH11, C16orf63, 
ABCC1, ABCC6, NOMO3 
POF-11 27 No 
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We specifically focused on microdeletions, as genomic losses are more likely to result in 
a clinical phenotype than genomic gains 69.  Eight women with POI exhibited novel hemizygous 
microdeletions greater than 0.1 Mb in size.  These were present on chromosomes 8, 10, 14, 15, 
18, and X.  Although our study focused on autosomes, we detected one novel interstitial 
microdeletion on the X chromosome in a woman with secondary amenorrhea, which mapped to 
Xp11.23-p11.22 where the BMP15 gene is located (Table 6).   
qPCR was utilized to verify the novel autosomal microdeletions.  A 2-Δ Δ Ct (fold change) 
quantification analysis was performed with the standard error of the mean Ct difference for each 
group of replicates given as the error bars.  Using this method, the initial amount of DNA can be 
determined by when the sample reaches a standardized concentration threshold. The fold change 
was plotted against the mean intensity shift (log R ratio), as measured on the array and shown in 
the GenomeStudio software (Figure 1).  All plotted microdeletions showed considerable fold 
reductions, as indicated by the top bars that lie below the shaded region (2n = diploid).  A cutoff 
value of 0.8 was used to determine diploid status. Six of the novel autosomal microdeletions 
contained coding regions, and five of the deletions were verified by qPCR analysis:  8q24.13, 
10p15-p14, 10q26.3, 15q25.2, and 18q21.32 (Table 6). 
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Figure 1. Data from SNP arrays and qPCR plotted as log R ratio and 2-Δ Δ Ct for five autosomal 
microdeletions in women with POI66 
Microdeletions were found in a higher frequency in women with primary amenorrhea 
compared to women with secondary amenorrhea. Two of the seven genotyped women with 
primary amenorrhea (29%) had novel microdeletions as compared to 6/81 women with 
secondary amenorrhea or unknown presentation (7%).  Of the nineteen total women with novel 
microdeletions or microduplications detected, one individual had a family history of POI in her 
sister and aunt (POF-87).  This patient had one novel microdeletion present at 15q25.2, and two 
novel microduplications present, one at 2p16.3 and another at 3p26.1 (see Tables 6 and 7). 
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5.0  DISCUSSION 
5.1 NOVEL CNV’S DETECTED BY SNP ARRAY 
Genomic studies in the search for causes of complex diseases have led to the discovery that 
CNV's play a role in several common diseases.  To date, only a few research groups have 
published data on copy number variants in women and families with POI.   
Aboura et al studied 99 Caucasian women, using a BAC array to identify CNV’s.  Eight 
statistically significant CNVs were identified, 7 on autosomes and 1 on the X chromosome62 but 
none was considered novel.  Five genes involved in reproduction were present in the CNV’s and 
the authors concluded they may be potential candidate genes for POI62.  These included DNAH5, 
NAIP, DUSP22, NUPR1, and AKT162.   
Another study focused on findings CNV’s on the X chromosome63.  Forty-two women 
with idiopathic POI were studied using an X/Y tiling path BAC array to identify CNV’s that may 
be involved in POI63. Fifteen CNV’s were discovered on both Xp and Xq that associated with 
POI63.  Genes located in these CNV regions included genes already thought to be associated with 
POI such as POF1B, as well as many others that may represent new candidate genes63.  This 
study also utilized a 1 Mb autosomal array; no CNV’s were discovered on autosomes, likely due 
to the lower resolution of the array63.  
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Another study utilized array CGH on 74 patients with POI or ovarian dysgenesis and 
found 15 microdeletions and 29 microduplications with only 4% present on the X chromosome29.  
The authors focused their discussion on deletions and duplications containing genes that may be 
involved in fertility29.  The authors concluded that a majority of the genes present in the 
rearrangements were genes involved in meiosis, DNA repair, or ovarian folliculogenesis29.   
Knauff and colleagues utilized a SNP array to find CNV’s on the X chromosome in 108 
Caucasian women with POI compared to 235 healthy women as controls70.  After validation of 
CNV’s by another custom designed X chromosome 60K array, there were no pathogenic CNV’s 
detected in the POI cohort70.  The authors suggested that although surprising, it may be possible 
that only large deletions/duplications on the X chromosome cause POI70.  All four of the studies 
reported in the literature have small sample sizes and report numerous CNV’s that have not yet 
been replicated in other women with POI.  Furthermore, the studies failed to identify CNV’s that 
could account for a majority of the POI experienced in their patients. 
Our study specifically focused on autosomal microdeletions due to the overwhelming 
data from mice studies suggesting that autosomal genes are critical for ovarian development9.  
Mouse models include mice with prenatal ovarian failure and postnatal ovarian failure and make 
it possible to begin to understand the relationship between certain genes, folliculogenesis, and 
ovarian function9.  More than thirty mouse models are used in research laboratories to study 
ovarian function, with the majority of the genes that are knocked out found on autosomal 
chromosomes rather than the X chromosome9. Furthermore, genomic losses are more likely to 
result in a clinical phenotype than duplications and past POI research has focused on X 
chromosome aberrations rather than autosomal ones8.  We have identified a total of eight novel 
microdeletions among 88 women with POI.  Five of six autosomal microdeletions that contained 
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known gene-coding regions were verified by qPCR.  The last two novel microdeletions were not 
verified by qPCR;  the deletion found on chromosome 14 of POF-66 did not contain any known 
genes, miRNA, or other non-coding RNAs, while the deletion found in POF-37 was present on 
the X chromosome. 
There were a total of 92 genes involved in the novel microdeletions found in our POI 
cohort.  Of these, two have been found to be linked to abnormal reproductive phenotypes in 
knock-out mice models, SYCE1 and CPEB1.  Synaptonemal complex central element protein 
(SYCE1) is located at 10q26.3 and has been shown to be an important structural component of 
the synaptonemal complex in males and females71.  SYCE1 knockout mice are infertile, with 
knockout ovaries being minute and knockout testes being only 20-30% the size of wild-type 
testes71.  Histologically, knockout ovaries contained no follicles and the knockout testes 
contained mostly primary spermatocytes, indicating an arrest in prophase I71.  Therefore, 
secondary amenorrhea at age 21 and POI in patient POF-108 may be due to heterozygous loss of 
the SYCE1 gene and loss of functional oocytes.   
Cytoplasmic Polyadenylation Element-Binding Protein 1 (CPEB1) is located at 15q25.2 
and is known to be expressed in oocytes72.  Studies have shown that adult female knockout mice 
have no oocytes present in their ovaries, and midgestational embryos had oocytes present that 
were arrested in pachytene72.  The authors concluded that CPEB1 was important in forming the 
synaptonemal complex72.  As with SYCE1, happloinsufficiency of CPEB1 may have played a 
role in the primary amenorrhea experienced by patient POF-87.  This patient also had a family 
history of POI in her sister and aunt.  Details of their age of onset or other medical history are 
unknown.  Knowing the genetic status of other family members, including affected and 
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unaffected individuals, could help delineate if haploinsufficiency of this region and specifically 
the CPEB1 gene is the cause for the familial POI.  
Although we focused on autosomal microdeletions, one deletion was present on the X 
chromosome of one of the subjects (POF-37).  This deletion spanned almost 4 Mb and contained 
65 genes, including BMP15.  BMP15 is known to play a role in folliculogenesis, with studies 
identifying mutations in BMP15 in women with primary and secondary amenorrhea30.  The 
presence of this gene within the large deletion on the X chromosome of this subject may provide 
a reason for this individual’s secondary amenorrhea experienced at age 34.   
The remaining microdeletions identified in our study harbor genes that are not known to 
play a role in reproductive biology.  We used microarray data generated from wild-type newborn 
mouse ovaries, as well as NCBI EST databases (Unigene and Gene Expression Omnibus), to 
determine whether any of the genes involved in the microdeletions detected are expressed in 
mammalian ovaries73.  POF-119 harbored a deletion that resulted in deletion of one copy each of 
CCBE1 and PMAIP1.  Based on these data sets, both CCBE1 and PMAIP1 are expressed in 
mouse ovaries.  Additionally, CTNNA3 (POF-85), ANKRD22 and STAMBPL1 (POF-58) 
transcripts are present in the murine ovarian transcriptome.  It is possible that such genes, as well 
as the others seen in our microdeletions and microduplications, play a role in ovarian 
development that has yet to be discovered.   
Seventeen novel microduplications were identified by the SNP arrays and were not 
present in the DGV.  Consequences of microduplications are harder to interpret than those of 
microdeletions. Therefore, our focus lay on analyzing and corroborating the novel deletions 
detected by the array.  Of the microduplications found in our cohort, two individuals harbored 
almost identical duplications on chromosome one, POF-21 and POF-106.  These 
  37 
microduplications included genes HSD3B2 and HAO2, both of which are expressed in ovaries of 
mice according to the Unigene and BioGPS databases with HSD3B2 also being expressed in the 
adrenal glands of mice.  The functional role of HAO2 in the ovary has not yet been determined.   
Hydroxy-delta-5-steroid dehydrogenase (HSD3B2, MIM 201810) is known to be 
involved in steroid hormone production.  Mutations in this gene have been found in individuals 
with congenital adrenal hyperplasia with variable presentation.  Virilization can occur in 
genetically female patients and under-virilization can occur in genetically male patients74.  In the 
severe form, salt wasting and salt loss can be a common cause of death in individuals.   Fertility 
can sometimes be an issue for individuals affected with this form of adrenal hyperplasia due to 
the inability of the body to produce a normal amount of sex hormones such as testosterone, 
androgen, and estrogen74.  Studies have reported increased expression of HSD3B2 in the theca 
cells of women with polycystic ovary syndrome, a frequent cause of infertility in women75.  A 
possible explanation of POI in our patient with a duplication of this gene is an imbalance of 
androgen and estrogen levels leading to the disruption of folliculogenesis.  However, further 
studies are warranted to test this hypothesis.  
5.2 LIMITATIONS OF STUDY AND FUTURE DIRECTIONS 
There are multiple limitations to the current study design.  Our cohort of 89 subjects is small, and 
a larger cohort of women is warranted. Larger sample sizes can aid in confirmation of the novel 
microdeletions detected in this pilot study, as well as identify more significant CNV’s that may 
be present in a larger proportion of women with POI.  Furthermore, animal studies modeling the 
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novel microdeletions and microduplications seen in patients with POI may help delineate the 
importance of CNV’s seen in these women. 
SNP arrays are not capable of covering the entire genome to date.  Additional CNV’s 
may be present in our cohort of women with POI, as high resolution arrays may cover only 50% 
of the CNV’s in the genome76. 
The amount of information available on the subjects was limited in this pilot study.  In 
some cases, it was not known at what age amenorrhea was first experienced, which is helpful in 
determining whether the individual had primary or secondary amenorrhea.  Family history was 
limited in this study as well.  POI is thought to be familial in 4-31% of cases and a detailed 
family history with particular attention paid to ages of menstruation and cessation, as well as any 
immune disorders, mental retardation, or environmental exposures can help determine if there is 
evidence of familial POI.  
Limited family data also can affect the analysis of a given CNV.  In women where a 
novel microdeletion is discovered, information as to whether the same CNV is present in 
affected and unaffected family members could aid in determining if the CNV is pathogenic or 
non-pathogenic.  However, reduced penetrance and variable expressivity have been reported in 
families with POI.  Therefore, identification of the same variant in an unaffected family member 
may not rule out pathogenicity of the CNV. 
The control population used in our pilot study may be limiting.  The DGV has been 
utilized in several studies. However its makeup of men and women may not make it the best 
control population for studies on ovarian function.  The DGV is composed of women who are 
considered healthy. However their complete menstrual history is not known and may not be 
appropriate for a study on POI.   
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Further studies are needed to assess the involvement of CNV’s in premature ovarian 
insufficiency.  The University of Pittsburgh is currently recruiting women with POI in the 
Pittsburgh area to continue identifying pathogenic CNV’s.  Recruitment of women with primary 
amenorrhea, as well as families with multiple individuals affected, may make finding genomic 
reasons for POI more likely.  A better control population will also aid in determining CNV 
affects.  Women who are known to have gone through natural menopause after the age of 45 and 
are known to be fertile, e.g. conceived children naturally, would aid in the future studies of 
CNV’s associating with POI.  
5.3 PUBLIC HEALTH SIGNIFICANCE 
Premature ovarian insufficiency is a devastating diagnosis for families and affects 1% of women 
under the age of 40 years and 0.1% of women under the age of 30.  With most cases of POI 
having an unknown cause, studies focusing on identifying genomic imbalances that may cause 
POI can lead to the discovery of more causes of this syndrome.  There are no known proven 
methods to assist women with POI to become pregnant naturally.  Discovering the genomic 
causes of the disease may lead to the development of safe treatment methods for these women.  
Furthermore, earlier detection of the disease, including before onset of amenorrhea, may aid in 
family planning for couples.    
 It is known that women with POI are at an increased risk for several common diseases, 
including osteoporosis and cardiovascular diseases and suffer from an increased overall mortality 
of 50%11.  Discovery of genes that are involved in POI may be determined to be risk factors for 
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overall morbidity and mortality and cardiovascular disease, thus aiding in the future management 
of patients known to have perturbations in these genes. 
 Further delineation of genomic imbalances in women with POI may indicate further 
genetic studies are warranted in the initial work up.  Fragile X studies and routine karyotype are 
the standard of care and studies on women with POI are finding genomic changes smaller than 
what can be detected by conventional karyotype.  In the future, array technology may be an 
important addition to the work up of women with POI. 
5.4 CONCLUSIONS 
We utilized SNP arrays technology to identify copy number variants in a cohort of 89 women 
with POI.  The Database of Genomic Variants (DGV) was used as a control population, aiding in 
the identification of seven novel autosomal microdeletions in our POI cohort, six of which 
contained gene-coding regions: 8q24.13, 10p15-p14, 10q23.31, 10q26.3, 15q25.2, and 18q21.32.  
Two of the novel microdeletions contained genes known to cause ovarian failure in knock-out 
mice models, SYCE1 and CPEB1.  One individual harbored a 4Mb deletion on one of her X 
chromosomes resulting in haploinsufficiency of 65 genes, including BMP15, which is a possible 
explanation for her secondary amenorrhea.  Seventeen novel microduplications were also 
detected, with the majority of CNV’s detected being on autosomal chromosomes rather than the 
X chromosome.  Two of the seven genotyped women with primary amenorrhea (29%) had novel 
microdeletions as compared to six of eighty women with secondary amenorrhea or unknown 
presentation (7%).  This pilot study demonstrates the role CNV’s play in POI and highlights the 
importance for studies with larger samples sizes to confirm the findings and further support the 
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hypothesis.  Identification of known genetic causes could aid in development of effective 
treatments for women with POI, as well as earlier diagnosis which may allow for family 
planning before the onset of amenorrhea.  Furthermore, array technology may be a useful 
addition to conventional karyotyping when evaluating women with POI. 
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H-10662-  GENETIC BASIS OF FEMALE FERTILITY (OOGENESIS) AND PREMATURE 
OVARIAN FAILURE
Background
Please read this information carefully.  If you have any questions please ask the study doctor or staff.  
Infertility or not being able to get pregnant after at least one year of trying affects 2.5-3.0 million couples 
in the U.S. yearly.  In 50% of all cases the reason is because of the female.  Each year nearly $2 billion 
is spent on infertility diagnosis and treatment. However, many female patients seen for infertility 
evaluation or premature ovarian failure (when a woman’s ovaries stop working before she is 40) are 
found to have no explanations for the problem. 
Study doctors know that in women with premature ovarian failure something happens to stop the normal 
functioning of the ovaries; but in most cases, the exact cause is not clear.  This results in an inability to 
diagnose specific problems, inability to offer accurate prognosis, and lack of effective treatment. 
Study doctors think that changes in genetic information may play an important role in infertility and 
premature ovarian failure (POF).  Therefore they want to study genes to see if there have been any 
changes.  In addition, study doctors are interested in also studying family members to find out whether 
genetic changes are related to infertility or POF.
This research study is sponsored by Baylor College of Medicine.
Purpose
The purpose of this study is to determine if there is a genetic cause for infertility or POF.  This will be 
done  by studying the genetic information in your blood or tissue sample.
Procedures
A total of  200 subjects at 1 institutions will be asked to participate in this study.  You will be one of 
approximately  200 subjects to be asked to participate at this location.
We are providing you with the information so you know that you are not the only one that is being asked 
to participate in the study. 
The research will be conducted at the following location(s): Baylor College of Medicine, TCH: Texas 
Children's Hospital, University of Pittsburgh Medical Center - Pennsylvania.
If you decide to participate, you will provide the study doctor with your medical and family history, 
information about premature ovarian failures or other gynecologic problems.  You will also provide the 
study doctor with one blood sample or a tissue sample, a questionnaire, and a pedigree of your family.  
We will send you the materials needed to get a blood sample.  We may also ask you for another sample 
of your blood if we are unable to obtain an adequate DNA sample from your blood or if we find new 
genetic information that may be important to the study.
We would like to get approximately  20cc or 4 teaspoons of blood from you to possibly find out  if the 
cause of ovarian failure or infertility is due to genetic changes.   You can come into our office and have a 
nurse draw blood from your vein in your arm.  You can also have your primary care physican or their 
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nurse draw the blood and mail the sample to our office.  If you would like to do this then we will be able 
to provide you with a laboratory order to have your primary doctor's office obtain the blood sample.  
Also, we will provide you with a blood collection kit , instruction sheet that tells you what to do with the 
sample once it is obtained and a FEDEX envelope with a pre-paid return mailer to send the sample to 
our office.  This blood will be used only to get genetic material (DNA). The blood sample is for research 
purposes only. We will only be looking at genes thought to be related to infertility and POF.  If tissue 
other than blood is already available or will become available, it may be analyzed in place of your blood
The tissue sample can be a sample that has already been removed by a past surgery or biopsy. We 
would like to use a small amount of tissue that is not needed by the pathologist ( the doctor that studied 
your tissue). We will only be examining tissue that would have otherwise been destroyed.  Only if excess 
tissue from any surgical specimen is available will it be used for this study. No surgery will be performed 
solely for the purpose of obtaining surgical specimens. Tissue samples used for the study will only be 
those obtained at an earlier time for previous testing. If you would like to provide us with a sample of 
your tissue then you will need to give us the name of your doctor that performed the surgery or biopsy or 
the doctor who ordered the procedure. We will also need you to provide us with a medical release form. 
The medical release form is a form that you sign that grants us permission to allow us to obtain the  
tissue from the doctors office.
Once we receive your blood and/or tissue specimen it  will be sent to the OB/GYN laboratory at Baylor 
College of Medicine for analysis.  Your specimen will be relabeled Unprocessed specimens will be 
frozen at -70C and stored in a locked freezer located in the principal investigator's laboratory. The 
remaining portion of the specimen(s) will be used to isolated DNA for genetic analysis. The sample will 
be banked at 4C and -20C, respectively, in locked refrigerator/freezers located in the principal 
investigator's laboratory. The results of your DNA analysis will be entered into a computerized database 
and reviewed by the pricipal investigator and his staff. Only the study doctor and their research assistant 
will have access to the original research data. Data will be completely confidential, and will not be 
revealed to family members, insurance companies, employers, or other individuals or organizations.
Your study records and medical records will be kept completely separate and no study data or 
information about your participation in the study will be entered into medical records. Your name will 
never appear on any reports of this study's findings. All specimens may be kept indefinitely. Your 
specimens will be discarded if the study is completed and no further experimentation is expected. You 
may withdraw from the study at any time. Your specimen will be destroyed upon withdrawal from the 
study. Your specimen will be available for other testing only following your authorization to the principal 
investigator. Your specimen(s) will not be transferred or sold in whole or part to any third party without 
obtaining written permission directly from you. The study doctor may contact you if he needs another 
blood sample from you. 
The results of you DNA analysis will be entered into a computerized database and reviewed by the 
principal investigator and his staff. Your DNA may be analyzed in the future as new test become 
available that are related to premature ovarian failure. The DNA will be analyzed only for genes 
(functional unit of hereditary material) related to premature ovarian failure. No additional research (i.e., 
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research not related to POF) will be performed on your DNA without your written permission. You may 
revoke your authorization for DNA research analyses at any time. In addition, if any DNA remains, you 
can request that it be destroyed and discarded at any time. All aspects of this study will be kept strictly 
confidential.  
These tests are being done for research purposes only; you and your doctor will not be informed of the 
results.
 
PEDIGREE CHART: You will complete a pedigree chart. A pedigree is like a family tree chart. It will 
identify family members that may have had problems with infertitlity or POF. We will give you a pedigree 
worksheet for you to complete. This form must be completed and returned to the study doctor or their 
coordinator. 
QUESTIONNAIRE: You will complete a brief questionnaire. The questionnaire will ask you questions 
about your menstrual history, how you were diagnosed with POF, medical and family history.  Please 
answer the questions as completely as possible. 
FAMILY MEMBERS
We are interested in studying your family regardless of whether they can or cannot have children to help 
us find out if  genetic changes are related to infertility or POF.  We will be asking you to provide 
information about this study to your family members in order to test their DNA. We will provide you with 
a separate form for you to provide to them so they can read and possibly participate in the study.  We 
may also ask to obtain additional samples of your family members blood if we are unable to obtain an 
adequate DNA sample from them or if we find new genetic information that may be important to the 
study.
The duration of your participation is limited to the time necessary to obtain blood or other tissue, to 
verify diagnosis and perform lab studies. This is expected to be 3 years or less. Blood or tissue will be 
stored and tested for newly detected genes that may be identified.
Your research doctor may be able to provide you with part of your information while the study is in 
progress. Test results will be revealed to you only at the discretion of the study doctor.
Unforeseeable and/or unknown risks/discomforts may occur. 
Blood draws: Having a blood sample taken by a medically trained person is a safe procedure, although 
occasionally there may be minor discomfort, and a bruise may develop around the needle puncture site. 
Some people may also occasionally feel faint or dizzy. Healthcare workers drawing the blood are aware 
of this, and they will watch you carefully before letting you get up from the chair in which you will be sitting 
when your blood is drawn.
Questionnaire:If you are unable to give information about your family's medical history, it may cause 
anxiety. It is okay if you are able to provide us with limited information you or your family knows.  
Potential Risks and Discomforts
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Pedigree- Although the risk is minimal it may cause anxiety. 
There is some risk associated with genetic testing for uncovering and conveying unwanted information 
regarding specific risk of disease or not providing any new information to you about POF.
Study staff will update you in a timely way on any new information that may affect your decision to stay in 
the study.
Potential Benefits
You will receive no direct benefit from your participation in this study.  However, your participation may 
help the investigators better understand genetic causes of infertility or POF. It is possible that future 
patients may profit from the result of this research.
Alternatives
You may choose to not participate in this study.
Investigator Withdrawal of Subject from a Study
The investigator or sponsor may decide to stop you from taking part in this study at any time. You could 
be removed from the study for reasons related only to you or because the entire study is stopped. The 
sponsor, investigator, Food and Drug Administration, or Institutional Review Board may stop the study 
at any time. 
You may withdraw from the study at any time and you may request that your sample be permanently 
removed if it has not already been used.
Subject Costs and Payments
You will be reimbursed for the costs associated with the blood draw and mailing only if you have 
someone other than the study staff draw the blood. You will receive up to $15 for blood draw charges.  
We will provide you with pre-paid shipping forms for blood that is mailed in to our office.
You will not be paid for taking part in this study.
Research personnel will try to reduce, control, and treat any complications from this research. If you are 
injured because of this study, you will receive medical care that you or your insurance will have to pay for 
just like any other medical care.
Subject's Rights
Your signature on this consent form means that you have received the information about this study and 
that you agree to be a part of the study. 
You will be given a copy of this signed form to keep.  You are not giving up any of your rights by signing 
this form.  Even after you have signed this form, you may change your mind at any time. Please contact 
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the study staff if you decide to stop taking part in this study.
The investigator or sponsor may decide to stop you from taking part in this study at any time. You could 
be removed from the study for reasons related only to you (for example, if you move to another city, if 
you do not take your study medication, or if you have a serious reaction to your study medication) or 
because the entire study is stopped. The sponsor may stop the study at any time.
There may be unknown risks/discomforts involved. Study staff will update you in a timely way on any new 
information that may affect your health, welfare, or decision to stay in this study.
If you are injured because of this study, you will receive medical care that you or your insurance will have 
to pay for just like any other medical care. You will not be paid for the injury. 
 
Your Health Information 
We may be collecting health information that could be linked to you (protected health information).  This 
protected health information might have your name, address, social security number or something else 
that identifies you attached to it.  Federal law wants us to get your permission to use your protected 
health information for this study.  Your signature on this form means that you give us permission to use 
your protected health information for this research study.
If you decide to take part in the study, your protected health information will not be given out except as 
allowed by law or as described in this form.  Everyone working with your protected health information 
will work to keep this information private.  The results of the data from the study may be published. 
However, you will not be identified by name. 
People who give medical care and ensure quality from the institutions where the research is being 
done, the sponsor(s) listed in the sections above, representatives of the sponsor,  and regulatory 
agencies such as the U.S. Department of Health and Human Services will be allowed to look at 
sections of your medical and research records related to this study.  Because of the need for the 
investigator and study staff to release information to these parties, complete privacy cannot be 
guaranteed.
The people listed above will be able to access your information for as long as they need to, even after 
the study is completed.  
If you decide to stop taking part in the study or if you are removed from the study, you may decide that 
you no longer allow protected health information that identifies you to be used in this research study.  
Contact the study staff to tell them of this decision, and they will give you an address so that you can 
inform the investigator in writing.  The investigator will honor your decision unless not being able to use 
your identifiable health information would affect the safety or quality of the research study.
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The investigator, ERTUG KOVANCI, and/or someone he/she appoints in his/her place will try to answer 
all of your questions. If you have questions or concerns at any time, or if you need to report an injury 
related to the research, you may speak with a member of the study staff: Aleksandar Rajkovic at 713- 
798-7500 during the day and/or Lisa  Marsh (713) 798-7549 during the day or after hours.  
Members of the Institutional Review Board for Baylor College of Medicine and Affiliated Hospitals (IRB) 
can also answer your questions and concerns about your rights as a research subject. The IRB office 
number is (713) 798-6970.
If your child is the one invited to take part in this study you are signing to give your permission. Each 
child may agree to take part in a study at his or her own level of understanding. When you sign this you 
also note that you child understands and agrees to take part in this study according to his or her 
understanding.
Please print your child's name here __________________________
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Signing this consent form indicates that you have read this consent form (or have had it read to you), 
that your questions have been answered to your satisfaction, and that you voluntarily agree to 
participate in this research study.  You will receive a copy of this signed consent form.
Subject Date
Legally Authorized Representative
Parent or Guardian
Date
Investigator or Designee Obtaining Consent Date
Witness (if applicable)
Translator (if applicable)
Date
Date
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